Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Becotatug Vedotin + PD-1 Inhibitor in HNSCC
NCT07683507Phase 2Not yet recruiting
- Start
- Jul 2026
- Primary completion
- Dec 2027
01
Overview
Phase 2, open-label trial of becotatug vedotin in head and neck squamous cell carcinoma (HNSCC) (2 cohorts). Primary endpoint: Objective Response Rate up to 2 years. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
becotatug vedotin
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07683507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07683507.